# Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™

> **NCT01358825** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 58 (actual)

## Conditions studied

- Tetanus
- Poliomyelitis
- Haemophilus Influenzae Type b
- Acellular Pertussis
- Diphtheria
- Hepatitis B
- Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

## Interventions

- **PROCEDURE:** Blood Sampling

## Key facts

- **NCT ID:** NCT01358825
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-30
- **Primary completion:** 2011-07-15
- **Final completion:** 2011-07-15
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2021-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358825, "Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01358825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*